This study will test the effectiveness of Engage & Connect, a 9-week remotely delivered psychotherapy for postpartum depression that focuses on reducing social isolation and helping mothers engage in more pleasurable activities.

Participants will be randomized to one of two groups, each consisting of 9 weekly therapy sessions. Randomization is like flipping a coin and there is a 50/50 chance of being assigned to either group.

Atypical choroid plexus papilloma (ACPP) and choroid plexus carcinoma (CPC) are both primary brain tumors that begin near the brain tissue. Choroid plexus carcinoma is fast-growing high-grade tumor, whereas atypical choroid plexus papilloma is an intermediate-grade tumor.

Removing these tumors through surgery has the best outcome for patients with ACPP or CPC, but there are often complications that can occur during the surgery. 

This is a clinical trial for adults with advanced solid tumors that have continued to grow despite the treatments already received.

This clinical research study is investigating different doses of a study drug called ARX517, to see which dose is safe and has the fewest side effects, and whether or not it is effective in reducing tumor size in participants with prostate cancer or advanced solid tumor(s) with known prostate-specific membrane antigen (PSMA) expression who failed prior standard therapies.
   

This clinical trial is for men and women with advanced solid tumors, such as advanced head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC).
   
The purpose of this study is to learn about the safety and effectiveness of combining two investigational anti-cancer drugs, tislelizumab (also known as BGB-A317) and BGB-A425. Investigational means that these drugs have not yet been approved by the U.S. Food and Drug Administration (FDA). 

This is a research study to evaluate if the oral medication doxycycline can slow lung damage caused by emphysema in people who also have HIV. This study will also evaluate the safety and tolerability of doxycycline.

The purpose of this study is to evaluate a study drug called CFI-400945, either by itself or in combination with one of two chemotherapy drugs, known as azacitidine or decitabine. The study aims to determine how safe this drug is at different doses, with food, and in combination with azacitidine or decitabine, and to measure how well each combination works for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML).

This study is looking at IO-202 as a potential new cancer treatment for acute myeloid leukemia (AML) or chronic myelomonocytic leukemia (CMML) when given alone and in combination with azacitidine.

IO-202 is an antibody, which is a protein that is part of the immune system that attaches to specific targets. The IO-202 antibody targets leukemia cells that carry a leukemia-associated protein. IO-202 is not approved by the U.S. Food and Drug Administration (FDA).It is currently being used for research purposes only.

The purpose of this study is to look at combining the study drug IMGN632 with standard therapies (azacitidine and/or venetoclax) for acute myeloid leukemia (AML). The study will look at what effects (both good and/or bad) this combination has on the cancer, how well this combination works to treat cancer, and what a safe dose of the study drug is.

IMGN5632 is considered experimental, meaning it has not yet been approved by the U.S. Food and Drug Administration (FDA) or other health authorities.

Participants will receive IMGN5632 in combination with venetoclax andazacitidine.

The purpose of this clinical research study to find out if the experimental drug, IDE397, is safe and helpful in those who have any type of cancer that is considered a “solid tumor” (not a blood cancer) that is caused by an error in the tumor DNA associated with the gene, methylthioadenosine phosphorylase (MTAP). The loss of the MTAP gene is an error seen in many different types of cancers. Participants must have loss of the MTAP gene in order to participate in the study.